Citation: Yonghui Sun, Xin Luo, Zimo Yang, Wenxing Lv, Lixia Chen, Hua Li, Yu Rao. Developing potent BTK^C481S PROTACs for ibrutinib-resistant malignant lymphoma[J]. Chinese Chemical Letters, ;2023, 34(6): 107924. doi: 10.1016/j.cclet.2022.107924 shu

Developing potent BTK^C481S PROTACs for ibrutinib-resistant malignant lymphoma

Yonghui Sun ^{a, 1} ,
Xin Luo ^{b, 1} ,
Zimo Yang ^a ,
Wenxing Lv ^a ,
Lixia Chen ^b ,
Hua Li ^{b, c, *,} ,
Yu Rao ^{a, *,}

a.
MOE Key Laboratory of Protein Sciences, School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Tsinghua University, Beijing 100084, China
b.
Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China
c.
Institute of Structural Pharmacology & TCM Chemical Biology, College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China

li_hua@hust.edu.cn

yrao@tsinghua.edu.cn

Received Date: 1 May 2022
Revised Date: 17 October 2022
Accepted Date: 18 October 2022
Available Online: 20 October 2022

Figures(6)

Ibrutinib is a first-line treatment drug for B-cell malignancies. However, resistance to ibrutinib has been reported due to BTK^C481S mutation. Although PROTAC strategy is expected to overcome this clinical resistance, it has limitations such as large molecular weight and moderate bioactivity, which restrict its potential clinical application. Herein, we report a new type of potent BTK^C481S-targeting PROTAC degrader. Through design, computer-assisted optimization and SAR studies, we have developed a representative BTK^C481S degrader L6 with a much smaller molecular weight and improved solubility. Notably, L6 demonstrates better BTK degrading activity and lower IC₅₀ value in ibrutinib-resistant cell line than the first-generation BTK degrader P13I. Optimization strategy of L6 provides a general approach in the development of PROTACs targeting BTK and other proteins for future study.
- Drug design,
- Ibrutinib resistance,
- BTK degraders,
- PROTACs,
- B-cell lymphoma
1. [1]
  B.D. Cheson, J.P. Leonard, N. Engl. J. Med. 359 (2008) 613-626. doi: 10.1056/NEJMra0708875
2. [2]
  L. Pasqualucci, D. Dominguez-Sola, A. Chiarenza, et al., Nature 471 (2011) 189-195. doi: 10.1038/nature09730
3. [3]
  L.M. Morton, S.S. Wang, S.S. Devesa, et al., Blood 107 (2006) 265-276. doi: 10.1182/blood-2005-06-2508
4. [4]
  J.C. Byrd, R.R. Furman, S.E. Coutre, et al., N. Engl. J. Med. 369 (2013) 32-42. doi: 10.1056/NEJMoa1215637
5. [5]
  J.A. Burger, A. Wiestner, Nat. Rev. Cancer 18 (2018) 148-167. doi: 10.1038/nrc.2017.121
6. [6]
  L.A. Honigberg, A.M. Smitha, M. Sirisawada, et al., Proc. Natl. Acad. Sci. U. S. A. 107 (2010) 13075-13080. doi: 10.1073/pnas.1004594107
7. [7]
  W.H. Wilson, R.M. Young, R. Schmitz, et al., Nat. Med. 21 (2015) 922-926. doi: 10.1038/nm.3884
8. [8]
  G. Li, X. Liu, X. Chen, Nat. Rev. Clin. Oncol. 17 (2020) 589-590. doi: 10.1038/s41571-020-0414-y
9. [9]
  J.A. Woyach, R.R. Furman, T. Liu, et al., N. Engl. J. Med. 370 (2014) 2286-2294. doi: 10.1056/NEJMoa1400029
10. [10]
  R.R. Furman, S. Cheng, P. Lu, et al., N. Engl. J. Med. 370 (2014) 2352-2354. doi: 10.1056/NEJMc1402716
11. [11]
  K.M. Sakamoto, K.B. Kim, A. Kumagai, et al., Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 8554-8559. doi: 10.1073/pnas.141230798
12. [12]
  G.E. Winter, D.L. Buckley, J. Paulk, et al., Science 348 (2015) 1376-1381. doi: 10.1126/science.aab1433
13. [13]
  A. Mullard, Nat. Rev. Drug Discov. 17 (2018) 777.
14. [14]
  X. Li, Y. Song, J. Hematol. Oncol. 13 (2020) 50. doi: 10.1002/jeq2.20016
15. [15]
  Y. Sun, X. Zhao, N. Ding, et al., Cell Res. 28 (2018) 779-781. doi: 10.1038/s41422-018-0055-1
16. [16]
  Y. Sun, N. Ding, Y. Song, et al., Leukemia 33 (2019) 2105-2110. doi: 10.1038/s41375-019-0440-x
17. [17]
  R.E. Davis, V.N. Ngo, G. Lenz, et al., Nature 463 (2010) 88-92. doi: 10.1038/nature08638
1. [1]
  Yang Liu , Yan Liu , Kaiyin Yang , Zhiruo Zhang , Wenbo Zhang , Bingyou Yang , Hua Li , Lixia Chen . A selective HK2 degrader suppresses SW480 cancer cell growth by degrading HK2. Chinese Chemical Letters, 2024, 35(8): 109264-. doi: 10.1016/j.cclet.2023.109264
2. [2]
  Bairu Meng , Zongji Zhuo , Han Yu , Sining Tao , Zixuan Chen , Erik De Clercq , Christophe Pannecouque , Dongwei Kang , Peng Zhan , Xinyong Liu . Design, synthesis, and biological evaluation of benzo[4,5]thieno[2,3-d]pyrimidine derivatives as novel HIV-1 NNRTIs. Chinese Chemical Letters, 2024, 35(6): 108827-. doi: 10.1016/j.cclet.2023.108827
3. [3]
  Liping Zhao , Xixi Guo , Zhimeng Zhang , Xi Lu , Qingxuan Zeng , Tianyun Fan , Xintong Zhang , Fenbei Chen , Mengyi Xu , Min Yuan , Zhenjun Li , Jiandong Jiang , Jing Pang , Xuefu You , Yanxiang Wang , Danqing Song . Novel berberine derivatives as adjuvants in the battle against Acinetobacter baumannii: A promising strategy for combating multi-drug resistance. Chinese Chemical Letters, 2024, 35(10): 109506-. doi: 10.1016/j.cclet.2024.109506
4. [4]
  Linghui Zou , Meng Cheng , Kaili Hu , Jianfang Feng , Liangxing Tu . Vesicular drug delivery systems for oral absorption enhancement. Chinese Chemical Letters, 2024, 35(7): 109129-. doi: 10.1016/j.cclet.2023.109129
5. [5]
  Fengjie Liu , Fansu Meng , Zhenjiang Yang , Huan Wang , Yuehong Ren , Yu Cai , Xingwang Zhang . Exosome-biomimetic nanocarriers for oral drug delivery. Chinese Chemical Letters, 2024, 35(9): 109335-. doi: 10.1016/j.cclet.2023.109335
6. [6]
  Yong-Dan Zhao , Yidan Wang , Rongrong Wang , Lina Chen , Hengtong Zuo , Xi Wang , Jihong Qiang , Geng Wang , Qingxia Li , Canqi Ping , Shuqiu Zhang , Hao Wang . Reversing artemisinin resistance by leveraging thermo-responsive nanoplatform to downregulating GSH. Chinese Chemical Letters, 2024, 35(6): 108929-. doi: 10.1016/j.cclet.2023.108929
7. [7]
  Yixuan Wang , Jiexin Li , Zhihao Shang , Chengcheng Feng , Jianmin Gu , Maosheng Ye , Ran Zhao , Danna Liu , Jingxin Meng , Shutao Wang . Wettability-driven synergistic resistance of scale and oil on robust superamphiphobic coating. Chinese Chemical Letters, 2024, 35(7): 109623-. doi: 10.1016/j.cclet.2024.109623
8. [8]
  Yuxin Li , Chengbin Liu , Qiuju Li , Shun Mao . Fluorescence analysis of antibiotics and antibiotic-resistance genes in the environment: A mini review. Chinese Chemical Letters, 2024, 35(10): 109541-. doi: 10.1016/j.cclet.2024.109541
9. [9]
  Bharathi Natarajan , Palanisamy Kannan , Longhua Guo . Metallic nanoparticles for visual sensing: Design, mechanism, and application. Chinese Journal of Structural Chemistry, 2024, 43(9): 100349-100349. doi: 10.1016/j.cjsc.2024.100349
10. [10]
  Ningyue Xu , Jun Wang , Lei Liu , Changyang Gong . Injectable hydrogel-based drug delivery systems for enhancing the efficacy of radiation therapy: A review of recent advances. Chinese Chemical Letters, 2024, 35(8): 109225-. doi: 10.1016/j.cclet.2023.109225
11. [11]
  Yihan Zhou , Duo Gao , Yaying Wang , Li Liang , Qingyu Zhang , Wenwen Han , Jie Wang , Chunliu Zhu , Xinxin Zhang , Yong Gan . Worm-like micelles facilitate the intestinal mucus diffusion and drug accumulation for enhancing colorectal cancer therapy. Chinese Chemical Letters, 2024, 35(6): 108967-. doi: 10.1016/j.cclet.2023.108967
12. [12]
  Xin Zhang , Junyu Chen , Xiang Pei , Linxin Yang , Liang Wang , Luona Chen , Guangmei Yang , Xibo Pei , Qianbing Wan , Jian Wang . Drug-loading ZIF-8 for modification of microporous bone scaffold to promote vascularized bone regeneration. Chinese Chemical Letters, 2024, 35(6): 108889-. doi: 10.1016/j.cclet.2023.108889
13. [13]
  Wenyi Mei , Lijuan Xie , Xiaodong Zhang , Cunjian Shi , Fengzhi Wang , Qiqi Fu , Zhenjiang Zhao , Honglin Li , Yufang Xu , Zhuo Chen . Design, synthesis and biological evaluation of fluorescent derivatives of ursolic acid in living cells. Chinese Chemical Letters, 2024, 35(5): 108825-. doi: 10.1016/j.cclet.2023.108825
14. [14]
  Lingling Su , Qunyan Wu , Congzhi Wang , Jianhui Lan , Weiqun Shi . Theoretical design of polyazole based ligands for the separation of Am(Ⅲ)/Eu(Ⅲ). Chinese Chemical Letters, 2024, 35(8): 109402-. doi: 10.1016/j.cclet.2023.109402
15. [15]
  Pingfan Zhang , Shihuan Hong , Ning Song , Zhonghui Han , Fei Ge , Gang Dai , Hongjun Dong , Chunmei Li . Alloy as advanced catalysts for electrocatalysis: From materials design to applications. Chinese Chemical Letters, 2024, 35(6): 109073-. doi: 10.1016/j.cclet.2023.109073
16. [16]
  Zikang Hu , Hengjie Zhang , Zhengqiu Li , Tianbao Zhao , Zhipeng Gu , Qijuan Yuan , Baoshu Chen . Multifunctional photothermal hydrogels: Design principles, various functions, and promising biological applications. Chinese Chemical Letters, 2024, 35(10): 109527-. doi: 10.1016/j.cclet.2024.109527
17. [17]
  Xiaoliu Liang , Chunliu Huang , Hui Liu , Hu Chen , Jiabao Shou , Hongwei Cheng , Gang Liu . Natural hydrogel dressings in wound care: Design, advances, and perspectives. Chinese Chemical Letters, 2024, 35(10): 109442-. doi: 10.1016/j.cclet.2023.109442
18. [18]
  Yi Cao , Xiaojiao Ge , Yuanyuan Wei , Lulu He , Aiguo Wu , Juan Li . Tumor microenvironment-activatable neuropeptide-drug conjugates enhanced tumor penetration and inhibition via multiple delivery pathways and calcium deposition. Chinese Chemical Letters, 2024, 35(4): 108672-. doi: 10.1016/j.cclet.2023.108672
19. [19]
  Ruikui YAN , Xiaoli CHEN , Miao CAI , Jing REN , Huali CUI , Hua YANG , Jijiang WANG . Design, synthesis, and fluorescence sensing performance of highly sensitive and multi-response lanthanide metal-organic frameworks. Chinese Journal of Inorganic Chemistry, 2024, 40(4): 834-848. doi: 10.11862/CJIC.20230301
20. [20]
  Jiajia Lv , Jie Gao , Hongyu Li , Zeli Yuan , Nan Dong . Rational design of hydroxytricyanopyrrole-based probes with high affinity and rapid visualization for amyloid-β aggregates in vitro and in vivo. Chinese Chemical Letters, 2024, 35(5): 108940-. doi: 10.1016/j.cclet.2023.108940

Get Citation

PDF

XML

Metrics

PDF Downloads(5)
Abstract views(334)
HTML views(23)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Developing potent BTKC481S PROTACs for ibrutinib-resistant malignant lymphoma

Metrics

通讯作者: 陈斌, bchen63@163.com

Developing potent BTK^C481S PROTACs for ibrutinib-resistant malignant lymphoma